Article
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Gastroenterology - 1 Aug 2014
Andreone Pietro, Colombo Massimo G, Enejosa Jeffrey V, Koksal Iftihar, Ferenci Peter, Maieron Andreas, Müllhaupt Beat, Horsmans Yves, Weiland Ola, Reesink Henk W, Rodrigues Lino, Hu Yiran B, Podsadecki Thomas, Bernstein Barry
Abstract excerpt
BACKGROUND & AIMS: The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenotype worldwide. We evaluated whether ribavirin is necessary for ABT-450, ritonavir, ombitasvir, and dasabuvir to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.